Repligen Corporation (RGEN)
Stock Price:
$152.01 USD
-3.87 (-2.48%)
Updated Aug 6, 2020 11:30 AM EDT - Market open
Key Info
| Market Cap |
7.98B |
| Revenue (ttm) |
302.47M |
| Net Income (ttm) |
30.94M |
| Shares Out |
52.50M |
| EPS (ttm) |
0.60 |
| PE Ratio |
253.35 |
| Forward PE |
166.67 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 6, 2020 |
| Last Price |
$152.01 |
| Previous Close |
$155.88 |
| Change ($) |
-3.87 |
| Change (%) |
-2.48% |
| Day's Open |
156.96 |
| Day's Range |
151.16 - 157.40 |
| Day's Volume |
187,641 |
| 52-Week Range |
72.32 - 159.97 |
More Stats
| Market Cap |
7.98B |
| Enterprise Value |
7.69B |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
52.50M |
| Float |
48.67M |
| EPS (basic) |
0.58 |
| EPS (diluted) |
0.60 |
| FCF / Share |
0.81 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
0.39% |
| FCF Yield |
0.53% |
| Payout Ratio |
n/a |
| Shares Short |
1.57M |
| Short Ratio |
1.93 |
| Short % of Float |
3.68% |
| Beta |
1.05 |
| PE Ratio |
253.35 |
| Forward PE |
166.67 |
| P/FCF Ratio |
188.40 |
| PS Ratio |
26.39 |
| PB Ratio |
7.20 |
| Revenue |
302.47M |
| Operating Income |
45.30M |
| Net Income |
30.94M |
| Free Cash Flow |
42.36M |
| Net Cash |
291.95M |
| Net Cash / Share |
5.56 |
| Gross Margin |
50.46% |
| Operating Margin |
14.98% |
| Profit Margin |
10.20% |
| FCF Margin |
14.01% |
| ROA |
2.27% |
| ROE |
3.13% |
| ROIC |
10.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$163.43*
(7.51% upside)
Low
140
Current: $152.01
High
173
Target: 163.43
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2010 | 2009 |
|---|
| Revenue | 270 | 194 | 141 | 105 | 83.54 | 63.55 | 68.17 | 62.27 | 27.29 | 20.97 |
| Revenue Growth | 39.28% | 37.38% | 35.1% | 25.14% | 31.45% | -6.78% | 9.48% | 128.16% | 30.14% | - |
| Gross Profit | 151 | 108 | 74.19 | 57.42 | 48.29 | 35.53 | 43.01 | 35.10 | 20.17 | 15.46 |
| Operating Income | 36.08 | 25.99 | 14.01 | 19.22 | 17.85 | 12.76 | 22.96 | 11.38 | -0.37 | -5.77 |
| Net Income | 21.41 | 16.62 | 28.35 | 11.68 | 9.35 | 8.17 | 16.09 | 14.16 | -0.04 | -4.06 |
| Shares Outstanding | 48.34 | 43.77 | 38.23 | 33.57 | 32.88 | 32.50 | 31.67 | 30.91 | 30.78 | 30.75 |
| Earnings Per Share | 0.44 | 0.37 | 0.72 | 0.34 | 0.28 | 0.25 | 0.50 | 0.45 | - | -0.13 |
| EPS Growth | 18.92% | -48.61% | 111.76% | 21.43% | 12% | -50% | 11.11% | - | - | - |
| Operating Cash Flow | 67.22 | 32.77 | 17.45 | 7.52 | 15.05 | 18.40 | 25.93 | 13.44 | 3.23 | -2.45 |
| Capital Expenditures | -23.15 | -12.78 | -5.45 | -4.28 | -2.63 | -5.60 | -4.64 | -1.26 | -0.52 | -0.60 |
| Free Cash Flow | 44.06 | 19.99 | 12.00 | 3.24 | 12.43 | 12.80 | 21.30 | 12.18 | 2.71 | -3.05 |
| Cash & Equivalents | 537 | 194 | 174 | 142 | 72.22 | 58.90 | 61.82 | 40.26 | 49.83 | 53.33 |
| Total Debt | 263 | 103 | 99.25 | 95.27 | - | - | - | - | - | - |
| Net Cash / Debt | 274 | 90.33 | 74.51 | 46.96 | 72.22 | 58.90 | 61.82 | 40.26 | 49.83 | 53.33 |
| Assets | 1,400 | 775 | 744 | 289 | 146 | 128 | 119 | 97.01 | 72.29 | 71.42 |
| Liabilities | 340 | 159 | 152 | 120 | 23.49 | 16.56 | 14.76 | 12.89 | 5.21 | 5.30 |
| Book Value | 1,060 | 616 | 592 | 169 | 123 | 112 | 104 | 84.12 | 67.09 | 66.12 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Repligen Corporation |
| Country |
United States |
| Employees |
761 |
| CEO |
Tony J. Hunt |
Stock Information
| Ticker Symbol |
RGEN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Instruments & Supplies |
| Unique Identifier |
NASDAQ: RGEN |
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA kits, which are analytical test kits to quantitate the proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber module-bag-tubing sets. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.